Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ZYME is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
41 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 5 days ago
Red flags: 0
203 filers reported a long position in ZYME for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| EcoR1 Capital, LLC | $600.4M | 23M | Unchanged |
| Rubric Capital Management LP | $183M | 7M | Unchanged |
| BlackRock, Inc. | $111.1M | 4.3M | -6.7% |
| PERCEPTIVE ADVISORS LLC | $109.3M | 4.2M | +19.2% |
| BVF INC/IL | $95.4M | 3.6M | -2.3% |
| MORGAN STANLEY | $58.3M | 2.2M | -10.1% |
| BNP Paribas Asset Management Holding S.A. | $46.6M | 1.8M | -6.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | $40.8M | 1.6M | -8.6% |
| Assenagon Asset Management S.A. | $32.7M | 1.3M | +72% |
| Nextech Invest Ltd. | $29.1M | 1.1M | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.